What is the upside for KEMET Corporation (Kemet)?
On average, they expect KEMET's share price to reach $27.50 in the next twelve months. This suggests a possible upside of 39.0% from the stock's current price. View Analyst Price Targets for KEMET.
What are analysts'target prices for KEMET Corporation (Kemet)?
3 brokers have issued twelve-month target prices for KEMET's shares. Their forecasts range from $26.00 to $29.00. On average, they expect KEMET's share price to reach $27.50 in the next twelve months.
Should you buy Kempharm (kmph) stock based on options?
Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.
How were KEMET's earnings last quarter?
KEMET Co. (NYSE:KEM) released its quarterly earnings results on Thursday, May, 14th. The electronics maker reported $0.37 earnings per share for th...
Is KEMET a good dividend stock?
KEMET(NYSE:KEM) pays an annual dividend of $0.05 per share and currently has a dividend yield of 0.18%. The dividend payout ratio of KEMET is 2.33%...
Who are KEMET's key executives?
KEMET's management team includes the following people: Mr. William M. Lowe Jr. , CEO & Director (Age 66) Mr. Ronald James Assaf , Sr. VP, Gen....
Who are some of KEMET's key competitors?
Some companies that are related to KEMET include Trimble (TRMB) , Jabil (JBL) , IPG Photonics (IPGP) , Mercury Systems (MRCY) , Fabrinet (FN)...
What other stocks do shareholders of KEMET own?
Based on aggregate information from My MarketBeat watchlists, some companies that other KEMET investors own include Micron Technology (MU) , NVID...
What is KEMET's stock symbol?
KEMET trades on the New York Stock Exchange (NYSE) under the ticker symbol "KEM."
What is KEMET's stock price today?
One share of KEM stock can currently be purchased for approximately $27.21.
How much money does KEMET make?
KEMET (NYSE:KEM) has a market capitalization of $1.59 billion and generates $1.26 billion in revenue each year. The electronics maker earns $41.38...
How many employees does KEMET have?
KEMET employs 12,450 workers across the globe.
Who bought Kemet?
Is Realtime sourced from all markets?
FORT LAUDERDALE, Fla., April 29, 2020 (GLOBE NEWSWIRE) -- KEMET Corporation (“KEMET”) (NYSE: KEM) today announced that, in connection with the pending acquisition of KEMET by Yageo Corporation (“Yageo”)...
About Kemet Corporation
Realtime quote and/or trades are not sourced from all markets.
Golden Star Signal
KEMET Corporation, together with its subsidiaries, manufactures and sells passive electronic components under the KEMET brand worldwide. The company operates through two segments, Solid Capacitors, and Film and Electrolytic.
Stock Podcast
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
What are the different grades for stocks?
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
How many X is Zacks?
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
Is ZacksTrade a broker?
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
How much is KemPharm's net loss for Q1 2021?
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
When will KemPharm open?
Current consulting arrangements contractually continue through March 2022. KemPharm’s net loss for Q1 2021 was $10.3 million, or $0.54 per basic share and diluted share, compared to net loss of $5.8 million, or $1.92 per basic and diluted share for the same period in 2020.
What is KMPH in 2021?
Trading to commence effective with the open of business on October 19, 2021 CELEBRATION, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its shares of common stock have been approved for listing to The Nasdaq Global Select Market. Trading on the exchange will commence effective with the open of business on October 19, 2021, under KemPharm’s current tick
When is KemPharm's earnings call 2021?
(NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietar y prodrugs, today announced it has entered into agreements with certain of its holders of its existing warrants exercisable for 6,117,509 shares of its common stock, in the aggregate, pursuant to which such holders agreed to exercise their warrants for cash in exchange for the Company’s agreement to issue in a private placeme
When does the SDX patent expire?
(NASDAQ:KMPH) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.
Is KP879 a Schedule IV drug?
The Orange Book listing confirms that SDX, which is contained within AZSTARYS, is an NCE, which provides five years of market exclusivity that expires on May 7, 2026.
Is KemPharm under any obligation?
If approved, KP879 could be a Schedule IV product, and physicians who are treating patients seeking to overcome addictions to cocaine, methamphetamine or other stimulants may be able to prescribe KP879 with the knowledge that the product candidate could have a significantly lower potential for abuse.”.
